At a Glance
- Company: Recordati SpA; undisclosed PE bidder
- Location: Milan, Italy (Recordati; listed on Borsa Italiana)
- Deal value: €10.9 billion takeover bid
- Focus area: Specialty pharma, rare diseases, urology, CNS
- Next steps: Board review; regulatory and shareholder approvals
What happened?
A private equity firm has submitted a €10.9 billion takeover proposal for Recordati, the Milan-listed specialty pharmaceutical group. The offer represents one of the largest PE-led buyout bids in European pharma in recent years and would take Recordati private if accepted.
Why does it matter?
Recordati has built a strong position in rare diseases, urology and CNS across Europe and international markets, generating consistent growth and high margins that make it an attractive PE target. A deal at this scale would rank among the most significant leveraged buyouts in European life sciences, signalling continued appetite from private capital for durable, cash-generative pharmaceutical businesses amid a challenging broader M&A environment.
Who’s behind it?
Recordati was founded in Milan in 1926 and is majority-controlled by the CVC Capital Partners-led consortium that took a controlling stake in 2018. The new bid introduces a further layer of private equity interest, suggesting a potential secondary buyout or full take-private of the remaining public float by another major sponsor.
How was it achieved?
The €10.9 billion offer is understood to reflect a premium to Recordati’s recent market capitalisation, consistent with PE deal structures requiring a control premium to gain board and shareholder support. The approach comes as Recordati continues to expand its rare disease portfolio through bolt-on acquisitions and organic pipeline growth.
What’s next?
Recordati’s board is expected to review the proposal and engage financial and legal advisers before making a formal recommendation to shareholders. Regulatory review across multiple European jurisdictions will be required, and the existing controlling shareholders will play a decisive role in determining whether the bid progresses to a formal offer or triggers a competitive process.